European Urology

Abstract

Objectives

To investigate the effects of darifenacin controlled-release (CR) and oxybutynin extended-release (ER) on cognitive function (particularly memory) in older subjects.

Methods

Healthy subjects (n = 150) ≥60 years were randomised to darifenacin, oxybutynin ER or placebo in a multicentre, double-blind, double-dummy, parallel-group, 3-week study. Doses were administered according to US labels: oxybutynin ER 10 mg once daily (od), increasing to 15 mg od then 20 mg od by week 3; darifenacin 7.5 mg od in weeks 1 and 2, then 15 mg od in week 3. The primary end point was accuracy on the Name–Face Association Test (delayed recall) at week 3.

Results

Results of the Name–Face Association Test at week 3 showed no significant difference between darifenacin and placebo on delayed recall (mean difference, −0.06, p = 0.908). In contrast, oxybutynin ER resulted in memory impairment, with significantly lower scores than placebo and darifenacin (mean differences, −1.30, p = 0.011 and −1.24, p = 0.022, respectively) for delayed recall on the Name–Face Association Test at week 3. Additional tests of delayed recall indicated significant memory impairment with oxybutynin ER versus placebo at certain time points, whereas darifenacin was similar to placebo. No between-treatment differences were detected in self-rated memory, demonstrating that subjects were unaware of memory deterioration.

Conclusions

While darifenacin had no significant effects on memory versus placebo, oxybutynin ER caused significant memory deterioration (magnitude of effect comparable to brain aging of 10 years). The results also demonstrate that subjects may not recognise/report memory deterioration.